Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202005118 Diagnosis of vertigo syndromes by integrated oculomotor and vestibular parameters New Medical Device NA
N202006011 A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) New Drug Phase Ⅲ
N202008042 A Phase 3, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of U101 Oral Capsules in the Preventio n of Uncomplicated Recurrent Urinary Tract Infections (rUTIs) in Women New Drug Phase Ⅲ
N202010029 A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08) New Drug Phase Ⅰ
N202010033 Feasibility of using Bortezomib with or without chemotherapy in patients with atypical teratoid/rhabdoid tumors New Drug (New Indication) Phase Ⅱ
N202010039 A Phase II Study to Evaluate the Efficacy and Safety of FB825 in Adult Patients with Moderate-to-severe Allergic Asthma New Drug Phase Ⅱ
N202010052 A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Ver sus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFRMutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer New Drug Phase Ⅲ
N202011014 A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) New Drug Phase Ⅲ
1 2 3 4 5 6 7 8 9 10 51 52 / 52

TOP